



**Food &
Function**

Blueberry phenolics are associated with cognitive enhancement in supplemented healthy older adults

Journal:	<i>Food & Function</i>
Manuscript ID	FO-ART-08-2020-002125.R1
Article Type:	Paper
Date Submitted by the Author:	25-Nov-2020
Complete List of Authors:	Rutledge, Grant; USDA-ARS Human Nutrition Research Center on Aging, Neuroscience & Aging Sandhu, Amandeep; Illinois Institute of Technology, Food Science and Nutrition Miller, Marshall; USDA-ARS Human Nutrition Research Center on Aging, Neuroscience & Aging Edirisinghe, I.; Illinois Institute of Technology, Food Science and Nutrition Burton-Freeman, Britt; Illinois Institute of Technology, Food Science and Nutrition Shukitt-Hale, Barbara; USDA-ARS Human Nutrition Research Center on Aging, Neuroscience & Aging

SCHOLARONE™
Manuscripts

1 Blueberry phenolics are associated with cognitive enhancement in supplemented healthy older
2 adults

3

4 Grant A. Rutledge,^a Amandeep K. Sandhu,^b Marshall G. Miller,^a Indika Edirisinghe,^b Britt B.
5 Burton-Freeman,^b and Barbara Shukitt-Hale^{*a}

6

7 ^aUSDA-ARS, Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA

8 ^bDepartment of Food Science and Nutrition, Illinois Institute of Technology, Chicago, IL, USA

9

10

11 *Correspondence to:

12 Barbara Shukitt-Hale, Ph.D.

13 USDA, HNRCA at Tufts University

14 711 Washington Street

15 Boston, MA 02111

16 Tel: 617-556-3118; Fax: 617-556-3299

17 E-Mail: barbara.shukitthale@usda.gov

18

19

20

21 Keywords: Blueberry, Cognition, Aging, Phenolic Acids, Anthocyanins

22

23

24

25

26 **Abstract**

27 Blueberries (BB) contain an array of bioactive phenolic compounds that may play a
28 protective role against various age-related diseases. Here we explored the metabolic fate of BB
29 phenolics and their relationship to cognitive function after chronic (90 days) supplementation of
30 freeze-dried BB (24 g/d, equivalent to 1 cup of fresh BB) or control in a randomized, double-blind,
31 parallel study with 38 healthy older adults (60-75 years). Blood samples were collected at fasting
32 ($t = 0$ h) and 2 h after a breakfast meal on days 0 (no treatment), 45, and 90, and a battery of
33 cognitive tests was also conducted on these days. Hippuric acid, phloroglucinaldehyde, syringic
34 acid, ferulic acid-glucuronide, cyanidin-3-*O*-galactoside, cyanidin-3-*O*-glucoside, malvidin-3-*O*-
35 galactoside, malvidin-3-*O*-glucoside, peonidin-3-*O*-xyloside, peonidin glucuronide, and
36 petunidin-3-*O*-glucoside concentrations were significantly altered after 90 days of BB
37 consumption compared to control. Stepwise regression was used to assess the relationship between
38 significantly altered concentrations of plasma phenolics and observed improvements in cognition.
39 Among participants in the BB group, changes in switch errors on the task-switching test (TST)
40 from day 0 to 90 were associated with changes in postprandial levels of plasma ferulic acid-
41 glucuronide, syringic acid, and malvidin-3-galactoside ($R^2 = 0.521, p < 0.05$). Changes in repetition
42 errors on the California Verbal Learning Test (CVLT-II) from day 0 to 90 were associated
43 with changes in postprandial levels of ferulic acid-glucuronide, syringic acid, and hippuric acid
44 ($R^2 = 0.807, p < 0.001$). These findings demonstrate that the addition of easily achievable quantities
45 of BB to the diets of older adults significantly alters levels of circulating phenolic compounds
46 which are related to improvements in cognition.

47

48

49 **Introduction**

50 Aging is often accompanied by declines in cognitive function, leading to lower quality of
51 life and increased need for care among older adults.¹ Diets rich in fruits and vegetables can reduce
52 the risk of age-related cognitive impairment, in part due to the presence of bioactive
53 phytochemicals in these foods, e.g., polyphenols.² Studies in aged rats demonstrate that berry
54 polyphenols are bio- and neuro-available, many of which have been linked to improvements in
55 cognitive performance.³

56 Blueberries (BB), in particular, have received increased attention due to their potential
57 neuroprotective effects.⁴ Dietary interventions with BB have shown improvements in cognitive
58 function in rodents^{5,6} and humans.⁷⁻¹⁰ In a recent 90-day randomized, placebo-controlled clinical
59 trial in healthy older adults (ages 60-75) who consumed 24g/d freeze-dried BB, our research group
60 reported improved executive function and memory relative to the control, when retested on days
61 45 and 90.⁸ Specifically, significant effects were observed on the Task-switching test (TST)¹¹⁻¹³
62 with subjects in the BB group showing reduced switch cost compared to those in the control
63 group.⁸ Significant effects were also observed on the California Verbal Learning Test (CVLT-
64 II),¹⁴ with subjects consuming the BB showing lower repetition errors compared to the control
65 group.⁸ However, the mechanism of action underlying these and other cognitive benefits of BB
66 has not yet been identified.¹⁵

67 BBs have a unique polyphenol profile and are an excellent source of various anthocyanins
68 and other phenolic compounds such as proanthocyanidins, chlorogenic acids, and flavonols.^{16,17}
69 Only a few clinical trials investigating the health benefits of chronic BB supplementation have
70 studied the polyphenol metabolites present in the plasma and urine following consumption. One
71 such study investigated the profile of plasma polyphenol metabolites after acute and daily

72 consumption of BB for 30 days in 18 healthy men (18-70 years).¹⁵ They concluded that BB
73 polyphenols are extensively absorbed and metabolized by the gut microbiota and phase II
74 enzymes, leading to an array of metabolites that may contribute to the health benefits observed
75 following BB supplementation. However, this study measured polyphenol concentrations in the
76 plasma and urine of individuals supplemented with BB for only 30 days. Understanding the
77 metabolic fate of BB polyphenols in an older population for a longer duration of supplementation
78 can help develop dietary recommendations that maximize cognitive improvement.

79 The present study aimed to explore changes in the concentrations of anthocyanins and
80 phenolic acid metabolites in plasma samples that were collected from a recently published
81 randomized, double-blind, 2-arm, parallel study that reported cognitive effects in healthy older
82 adults supplemented with BB or control.⁸ Blood samples were collected after an overnight fast
83 (~12-15 h) and 2 h postprandially on days 0, 45, and 90. Regression analysis was performed on
84 phenolic compounds that were significantly increased in the BB group compared to the control
85 group and measures of cognitive function. We hypothesized that dietary supplementation with BB
86 would increase the concentrations of circulating polyphenols in plasma of healthy older adults,
87 and the changes would be associated with enhanced cognitive functions.

88

89

90

91

92

93

94

95 **Methods**

96 **Design and procedures**

97 Informed consent was obtained from all study participants. This study was approved by the
98 Tufts University Institutional Review Board and registered on clinicaltrials.gov (clinicaltrials.gov
99 identifier: NCT01888848). Screened participants were enrolled in a double-blind, placebo-
100 controlled, 2-arm, chronic feeding trial. Participants visited the USDA Jean Mayer Human
101 Nutrition Research Center on Aging (HNRCA) at Tufts University in Boston, MA on four different
102 occasions: a practice visit (visit 1), a baseline visit (day 0, visit 2), a mid-point visit (day 45, visit
103 3), and a final visit (day 90, visit 4) (Fig. 1).

104 Visit 1 was a practice visit to familiarize study participants with the procedures of the study.
105 Upon arrival at the HNRCA for the baseline visit (day 0, visit 2), fasting (~12–15 h) blood samples,
106 anthropometrics, and vital signs were collected by registered nurses. Participants then consumed
107 a standard breakfast consisting of a corn muffin, butter, apple juice, a banana, and coffee (~600
108 calories, 58 g sugar, and 21 g fat) within 15 minutes and were escorted to a testing room where
109 experimenters administered a battery of cognitive tests and questionnaires. Two hours after
110 consuming the breakfast, a second blood sample was collected by nurses. At the end of the visit,
111 participants were given their first drink (BB or control) and given enough supplements to last until
112 their midpoint visit (visit 3, day 45).

113 Upon arrival at the HNRCA for visit 3, participants provided a fasting blood sample before
114 and 2 h following the completion of breakfast. This standard breakfast also included the BB or
115 control drink according to their randomly assigned group. Upon finishing the midpoint visit's
116 cognitive tests and questionnaires, participants were sent home with additional supplement packets
117 to last them until their final visit. During visit 4, participants consumed their final supplement

118 packet with breakfast following the same study procedures as visit 3. More details on the design
119 of this clinical trial including recruitment, randomization, power calculations, and process drop
120 out are available in our published study on the cognitive effects of BB consumption.⁸

121

122 **Treatments**

123 Participants in the BB study group consumed 24 g/day of lyophilized, cultivated BB
124 (Tifblue variety; equivalent to 1 cup/day of BB; 12g powder in ~1 cup water taken with each
125 morning and evening meal). This dose of BB contained ~36 mg/g total phenolics, ~19.2 mg/g
126 anthocyanins and contributed ~90 kcal/day to the diet.⁸ (see Table S1 for phenolic composition of
127 the BB powder). Participants in the control group consumed 24 g of a seemingly identical,
128 isocaloric control powder comprised of maltodextrin, fructose, artificial and natural BB flavor,
129 artificial colors, and citric acid. Control and BB powders were provided by the US Highbush
130 Blueberry Council. Participants were instructed to abstain from consuming berry fruit or berry
131 containing products for the duration of the study but to otherwise maintain their usual diet.

132

133 **Participants**

134 Inclusion criteria included: men and women (60-75 years; BMI 18.5-29.9 kg/m²),
135 nonsmoker, English fluency, >12 months postmenopausal, adequate vision for computer use, and
136 in otherwise good health (i.e., no history of cardiovascular, metabolic, respiratory, renal, hepatic
137 or gastrointestinal diseases). Exclusion criteria included: medications or dietary supplements that
138 would interfere with the outcomes of the study, mini-mental status exam <24, illicit drug use, at
139 risk for falls, impaired mobility, neurological disorders, presenting with cognitive deficits,
140 consuming >2 alcoholic drinks per day, vegetarians or vegans, and allergies or sensitivity to berries

141 or berry containing products.

142

143 **Dietary assessment and compliance**

144 Participants completed the National Cancer Institute's Diet History Questionnaire II
145 (DHQ-II) during study visit 1. This questionnaire assessed participants' diet over the previous 12
146 months. The DHQ-II is a comprehensive, 124-item inventory that collects information on specific
147 foods commonly consumed in the United States. Participants also completed an additional
148 questionnaire on overall berry consumption. Participants were contacted by telephone once a week
149 by one of the investigators to check supplement compliance and to monitor for adverse events and
150 changes in health history. To further track compliance, participants were instructed to record when
151 they consumed the supplements each day. Participants also returned empty and any unused
152 supplement packets each time they visited the center (visit 3 and 4), which were counted as an
153 additional check on compliance.

154

155 **Cognitive Tests**

156 The task-switching test (TST) was administered on days 0, 45, and 90 to assess executive
157 function. During the test, participants viewed four intersecting lines on a computer monitor. Digits
158 (1-4, 6-9) appeared, one at a time, in clockwise locations around the display. Participants
159 responded by pressing one of two buttons depending on whether the number appeared in the top
160 (odd vs. even) or bottom (>5 vs <5) half of the display. The TST took approximately 30 minutes
161 to complete. An abbreviated practice session was conducted during the practice visit (visit 1) to
162 familiarize participants with the task.

163 The standard and alternate versions of the California Verbal Learning Test (CVLT-II) were

164 administered, in counterbalanced order, on intervention days 0 and 90 to assess verbal learning
165 and memory. During the CVLT-II, an experimenter read a 16-word list (list A), containing words
166 from four semantic categories, and participants immediately recalled the list after each of 5
167 presentations. A 16-word distractor list (list B) was then presented for immediate recall, followed
168 by free recall and category-cued recall of list A. Following a 20-minute delay, free recall, category-
169 cued recall, and recognition of list A were tested. After a further 10-minute delay, forced
170 recognition of List A was tested (see Miller and colleagues⁸ for a more detailed description of the
171 cognitive tests administered in this clinical trial). The TST and CVLT-II data were previously
172 published in Miller and colleagues⁸.

173

174 **Sample preparation and HPLC analysis of anthocyanins and phenolic acid metabolites.**

175 Fasting and 2 h postprandial blood were collected on intervention days 0, 45, and 90 in
176 tubes containing EDTA as an anticoagulant. Blood samples were centrifuged at 453g for 15
177 minutes at 4°C. Plasma was separated immediately from buffy coat and red blood cells after
178 centrifugation and aliquots were stored at -80°C for batch analysis at the end of the study. Solid-
179 phase extraction (SPE) (Bond Elut Plexa, 200 mg, 3 mL, Agilent Technologies) was used for the
180 extraction of anthocyanins and phenolic acid metabolites from the plasma. Briefly, plasma was
181 thawed on ice and 400 µL of sample was diluted with 1.2 mL of acidified water (1% formic acid).
182 Samples were loaded on the pre-conditioned cartridges under gravity. The SPE cartridges were
183 washed with 1.5 mL of acidified water (1% formic acid). Elution of metabolites was done with 1.5
184 mL of acidified methanol (1% formic acid). The collected elute was dried under nitrogen at room
185 temperature. The dried sample was dissolved in acetonitrile (5% containing 1% formic acid), and
186 centrifuged at $18514 \times g$ for 10 min at 4 °C. Samples were transferred to amber HPLC vials and

187 were analyzed using an Agilent 1290 Infinity ultra-high pressure liquid chromatography (UHPLC)
188 system with an Agilent 6460 Triple Quadrupole Mass Spectrometer (Agilent Technologies, Santa
189 Clara, CA). The system was equipped with a binary pump with an integrated vacuum degasser, an
190 autosampler with a thermostat, and a column compartment with a thermostat. Separation of
191 anthocyanins and metabolites was conducted using poroshell 120 stablebond C18 column (2.1
192 mm×150 mm, 2.7 μm, Agilent Technologies) at a constant temperature of 35°C. The mobile phase
193 used for the separation of compounds consisted of acidified water (1% formic acid) and
194 acetonitrile. The injection volume was 5 μL. The flow rate was maintained at 0.3 mL/min and the
195 gradient was as follows: 5% B at 1 min, 18.5% B at 45 min, 90% B at 50 min, 5% B at 52 min and
196 8 mins for post run. Agilent Pursuit 3 PFP column (150 × 2.0 mm) with guard column (Pursuit 3
197 PFP MetaGurad 10 × 2.0 mm) was used for phenolic acids analysis. The column temperature was
198 set at 40 °C and the mobile phase used was acidified water (0.1% formic acid) and acidified
199 acetonitrile (0.1% formic acid). The solvent gradient was 5% B at 1 min, 10% B at 10 min, 15%
200 B at 3 min, 15% B at 7 min, 20% B at 9 min, 20% B at 10 min, 25% B at 11 min, 30% B at 13
201 min, 30% B at 14 min, 95% B at 15 min, 5% B at 16 min and 4 min for post run. Injection volume
202 was 5 μL. For quantification of compounds, standards were prepared in blank plasma (charcoal
203 stripped human plasma obtained from BioreclamationIVT, NY) for matrix match. Authentic
204 standards were used for quantification when available and metabolites were quantified using
205 parent compounds or compounds sharing similar chemical structure or molecular weight.

206

207 **Statistical Analyses**

208 All statistical analyses were performed using SYSTAT software (SPSS, Inc, Chicago, IL).
209 DHQ-II and demographic data were analyzed by Student's t-test. Phenolic acid and anthocyanin

210 metabolites were analyzed by two-way analysis of variance (ANOVA) followed by *post hoc*
211 testing with Fisher's LSD to determine differences between the groups. Data from the fasting and
212 postprandial timepoints were analyzed separately. A forward stepwise regression was performed
213 on the change (Day 90 – Day 0) in postprandial levels of polyphenols with significant treatment
214 by visit interactions from ANOVA and the change (Day 90 – Day 0) in task switching errors on
215 the TST and repetition errors on the CVLT-II. Switching errors and repetition errors were chosen
216 as dependent variables in each analysis because they were significantly lower in the BB group
217 compared to the control group.⁸ Results were considered statistically significant if the observed
218 significance level was $p < 0.05$.

219 Results

220 Subject demographics and compliance

221 The final analysis consisted of 38 participants of which 19 consumed the control powder
 222 and 19 consumed the BB powder. The average age and BMI of the groups are shown in Table 1.
 223 Age and BMI were not significantly different between the BB and control groups ($p > 0.05$; Table
 224 1). There was no difference in the number of missed supplement packets between the two groups
 225 ($p > 0.05$; Table 1).

226 **Table 1** Participant demographics and compliance

	Control	Blueberry
Number of participants (N)	19	19
Women	63%	72%
Age (years)	67.3 ± 4.8	67.8 ± 4.6
Baseline BMI (kg m ⁻²)	24.0 ± 2.5	24.1 ± 3.7
Compliance	99.2%	99.2%

Values presented as mean ± standard deviation.

227

228 Dietary assessment

229 Analysis of DHQ-II data at baseline revealed no significant differences between the control
 230 and BB groups for usual intake of key nutrients and food groups, however participants in the BB
 231 group reported consumption of significantly more tomatoes (0.311 vs. 0.187 estimated cups/day,
 232 $p < 0.05$) and eggs (11.25 vs. 4.48 grams/day, $p < 0.05$) compared to those in the control group.
 233 Participants assigned to the control group reported consumption of significantly more of the
 234 sweetener xylitol (0.033 vs. 0.021 grams/day, $p < 0.05$). The control and BB groups did not
 235 significantly differ in the frequency of berry fruit intake in general ($p > 0.05$) or intake of BB
 236 specifically ($p > 0.05$).

237 **Phenolic acid metabolites**

238 Fifteen phenolic acids and their conjugated metabolites were quantified in fasting (0 h) and
239 postprandial (2 h) plasma of participants on the control and BB supplements on days 0, 45, and 90
240 (Table 2). Among all the phenolic acids quantified, hippuric acid was present in the highest
241 concentration in fasting plasma of the BB group on day 45 ($80.8 \pm 8.4 \mu\text{mol L}^{-1}$ vs. 12.6 ± 3.0
242 $\mu\text{mol L}^{-1}$ in the control group). Significant intervention group (control and BB) by day (0, 45, and
243 90) interactions were observed for hippuric acid ($F(2, 72) = 21.81, p < 0.001$; Fig. 2A), syringic
244 acid ($F(2, 72) = 16.42, p < 0.001$; Fig. 2B), ferulic acid-glucuronide ($F(2, 72) = 4.04, p < 0.05$;
245 Fig. 2C), and phloroglucinaldehyde ($F(2, 72) = 10.05, p < 0.001$; Fig. 2D) at the postprandial
246 timepoint. Interestingly, hippuric acid was the only phenolic acid that was significantly altered at
247 the fasting timepoint ($F(2, 72) = 25.47, p < 0.001$; Fig. 2A). At the postprandial timepoint, a
248 significant intervention group effect was observed for hippuric acid ($F(1, 36) = 33.90, p < 0.001$;
249 Table 2), isovanillic acid ($F(1, 36) = 6.42, p < 0.05$; Table 2), phloroglucinaldehyde ($F(1, 36) =$
250 $40.57, p < 0.001$; Table 2), syringic acid ($F(1, 36) = 33.81, p < 0.001$; Table 2), and trans-cinnamic
251 acid ($F(1, 36) = 7.15, p < 0.05$; Table 2). At the fasting time-point, a significant intervention group
252 effect was observed for hippuric acid only ($F(1, 36) = 26.24, p < 0.001$; Table 2).

253 Further *post hoc* comparisons showed significantly higher concentrations of hippuric acid,
254 syringic acid, and phloroglucinaldehyde on days 45 and 90 in the BB group compared to the
255 control group at the postprandial timepoint ($p < 0.05$; Fig. 2). Furthermore, the BB group had
256 significantly higher concentrations of these phenolic acids at the postprandial timepoint on days
257 45 and 90 compared to baseline (day 0) ($p < 0.05$; Fig. 2). Hippuric acid was also significantly
258 increased at the fasting timepoint on days 45 and 90 compared to baseline (day 0) and the control
259 group ($p < 0.05$; Fig. 2A). Interestingly, concentrations of these phenolics did not significantly

260 differ between days 45 and 90 ($p > 0.05$; Fig. 2). No significant differences were observed for
261 ferulic acid-glucuronide at the fasting and postprandial timepoints ($p > 0.05$; Fig. 2C).

262

263 **Anthocyanins and their conjugated metabolites**

264 Fifteen anthocyanins and their conjugated metabolites were quantified in fasting (0 h) and
265 postprandial (2 h) plasma of participants on the control and BB supplements on days 0, 45, and 90
266 (Table 2). Anthocyanins and their metabolites were not significantly detected in plasma samples
267 from the control group or in samples collected at the baseline visit (day 0). Peonidin glucuronide,
268 a conjugated metabolite of peonidin, reached 150.7 ± 67.2 nmol L⁻¹ at 2 h on day 45 in the BB
269 group, which was the highest concentration among all phase II metabolites maintaining the parent
270 structure. Among the parent untransformed anthocyanins, the content of malvidin-3-*O*-galactoside
271 was highest (29.5 ± 8.6 nmol L⁻¹) in 2 h plasma sample on day 45 in the BB group. Significant
272 intervention group (control and BB) by day (0, 45, and 90) interactions were observed for cyanidin-
273 3-*O*-galactoside ($F(2, 72) = 5.34, p < 0.01$ Fig. 3A), cyanidin-3-*O*-glucoside ($F(2, 72) = 3.11, p$
274 $= 0.051$ *marginal*; Fig. 3B), malvidin-3-*O*-galactoside ($F(2, 72) = 8.40, p < 0.01$; Fig. 3C),
275 malvidin-3-*O*-glucoside ($F(2, 72) = 4.23, p < 0.05$; Fig. 3D), petunidin-3-*O*-glucoside ($F(2, 72)$
276 $= 3.18, p < 0.05$; Fig. 4A), peonidin glucuronide ($F(2, 72) = 5.33, p < 0.01$; Fig. 4B), and peonidin-
277 3-*O*-xyloside ($F(2, 72) = 7.65, p < 0.01$; Fig. 4C) at the postprandial timepoint only. A significant
278 intervention group effect was observed for all of the anthocyanin/metabolites studied ($p \leq 0.05$)
279 except delphinidin-3-*O*-galactoside, delphinidin-3-*O*-glucoside and peonidin-3-*O*-arabonide ($p >$
280 0.05 ; Table 2). No significant differences were observed at the fasting timepoint ($p > 0.05$; Table
281 2).

282 Further *post hoc* comparisons of postprandial samples from the BB group showed

283 significantly higher concentrations of cyanidin-3-*O*-galactoside (Day 45 and 90), cyanidin-3-*O*-
284 glucoside (Day 90), malvidin-3-*O*-galactoside (Day 45 and 90), malvidin-3-*O*-glucoside (Day 45
285 and 90), petunidin-3-*O*-glucoside (Day 45), peonidin glucuronide (Day 45 and 90), and peonidin-
286 3-*O*-xyloside (Day 45 and 90) compared to the control group ($p < 0.05$; Fig. 3-4). As observed
287 with the phenolic acids, the concentrations of these anthocyanins did not significantly differ
288 between days 45 and 90 ($p > 0.05$; Fig. 3-4), with the exception of peonidin glucuronide whose
289 concentration was significantly lower at day 90 compared to day 45, however still significantly
290 higher than baseline ($p < 0.05$; Fig. 4B).

291

292 **Regression analysis**

293 Overall change (Day 90 – Day 0) in the eleven phenolic acids and anthocyanins which
294 were enhanced in postprandial blood of BB group and change (Day 90 – Day 0) in repetition errors
295 in the CVLT-II or switching errors in the TST were entered into a forward stepwise regression.
296 Change in postprandial plasma levels of ferulic acid-glucuronide, syringic acid, and malvidin-3-
297 *O*-galactoside was associated with change in task switching errors ($R^2 = 0.521$, $p < 0.05$; Figures
298 5A-C). Change in ferulic acid-glucuronide was negatively associated with change in switching
299 errors ($\beta = -0.150$, $p < 0.01$; Fig. 5A). Change in syringic acid was negatively associated with
300 change in switching errors, however this was not significant ($\beta = -0.098$, $p > 0.05$; Fig. 5B).
301 Interestingly, change in malvidin-3-*O*-galactoside was positively associated with change in
302 switching errors ($\beta = 0.535$, $p < 0.05$; Fig. 5C).

303 Change (Day 90 – Day 0) in postprandial plasma levels of ferulic acid glucuronide, syringic
304 acid, and hippuric acid was associated with change (Day 90 – Day 0) in CVLT-II repetition errors
305 ($R^2 = 0.807$, $p < 0.001$; Fig. 5D-F). Change in concentration of syringic acid was also positively

306 associated with change in repetition errors ($\beta = 0.070, p < 0.001$; Fig. 5D). Change in concentration
307 of ferulic acid-glucuronide was positively associated with change in repetition errors ($\beta = 0.044,$
308 $p < 0.001$; Fig. 5E). Lastly, change in hippuric acid was negatively associated with change in
309 repetition errors ($\beta < -0.001, p < 0.001$; Fig. 5F).

310 **Discussion**

311 Prior to the current study, characterization of phenolic compound profiles in plasma after
312 BB supplementation had been performed up to 6 h after acute consumption,^{18,19} up to 24 h after
313 acute consumption,²⁰ and up to 2 h after chronic consumption of BB for 30 days.¹⁵ These studies
314 demonstrated that BB metabolites peak at different times during a 24 h period post-consumption
315 and some metabolites exhibit biphasic patterns.²⁰ Furthermore, chronic consumption of BB leads
316 to the retention and persistence of some phenolic acid compounds over a longer period than is
317 observed in acute studies.¹⁵ The purpose of this study was to quantify plasma phenolic acids and
318 anthocyanin concentrations in the plasma of healthy older adults supplemented with BB or control
319 over 90 days. To our knowledge, this is the first study to characterize BB polyphenol profiles after
320 90 days of chronic feeding in older adults. In addition, this is the first study to correlate plasma
321 phenolics with measures of cognitive function to further study the possible mechanisms of action
322 underlying the cognitive benefits observed with chronic BB intake.^{8,10,21,22} Plasma phenolic acid
323 and anthocyanin concentrations were significantly altered after 90 days of BB consumption
324 compared to the control, and concentrations of these plasma phenolics correlated with
325 improvements in cognition.

326 Anthocyanins were not significantly detected in fasting or postprandial samples from the
327 control group on days 0, 45, and 90 or on day 0 of samples from the BB group ruling out the
328 possibility that anthocyanins were present in blood circulation before participants started the study.
329 A significant group by day interaction was observed for seven anthocyanins (cyanidin-3-*O*-
330 galactoside, cyanidin-3-*O*-glucoside, malvidin-3-*O*-galactoside, malvidin-3-*O*-glucoside,
331 peonidin-3-*O*-xyloside, peonidin glucuronide, and petunidin-3-*O*-glucoside) in 2 h postprandial
332 samples. All anthocyanins quantified, except for delphinidin-3-*O*-galactoside, delphinidin-3-*O*-

333 glucoside, and peonidin-3-*O*-arabinoside were significantly elevated in 2 h postprandial, but not
334 fasting, samples from the BB group compared to the control (Table 2). These findings are in line
335 with previous research showing that anthocyanin concentrations peak around 2 h following acute
336 consumption of BB and decline back to baseline by 24 h.²⁰ Furthermore, an additional 45 days of
337 supplementation did not further increase the concentrations of anthocyanins in the plasma as was
338 observed in a previous chronic strawberry supplementation study, as there was no difference in
339 anthocyanin levels from day 45 to day 90.²³

340 Anthocyanins were not significantly detected in fasting (~12-15 h) plasma of subjects on
341 the BB supplement on days 45 and 90. However, this finding does not preclude the possibility that
342 anthocyanins accumulated in tissues, including the brain, following chronic consumption of BB.
343 Anthocyanins, including those found in BB, have a high affinity for animal tissues,²⁴ and it has
344 been demonstrated that anthocyanins can cross the blood-brain barrier.³ In a study with pigs,
345 anthocyanins were absent from fasting plasma and urine after chronic consumption of a BB-
346 enriched diet for 4 weeks, however anthocyanins were found in tissues from the eye, cortex, and
347 cerebellum.²⁵ Andres-Lacueva and colleagues³ fed BB to rats for 70 days and detected
348 anthocyanins in various regions of the brain, particularly the cortex. Zhong et al.²⁰ found that by
349 24 h post-consumption of a BB beverage, no anthocyanins were detected in subjects' plasma.
350 However, this was an acute study and plasma anthocyanin levels were not measured during 10-24
351 h post-consumption. In an acute pharmacokinetic study conducted with strawberries, anthocyanins
352 peaked 1-3 h post-consumption and were back to baseline concentrations 8-10 h post-
353 consumption.²⁶ In a previous study from our lab, subjects consumed 24 g d⁻¹ of freeze-dried
354 strawberry (equivalent to 2 cups of fresh strawberries) and anthocyanins were measured at fasting
355 and postprandial timepoints on days 0, 45 and 90.²³ Three anthocyanins/metabolites (pelargonidin

356 glucuronide, pelargonidin-3-rutinoside, and pelargonidin-2-glucoside) were detected in fasting
357 and 2 h plasma on days 45 and 90 suggesting that anthocyanins persisted in the blood of subjects
358 longer than what was found in previous acute studies.^{26,27} However, previous studies have shown
359 that blueberries do not contain pelargonidin,²⁸ and pelargonidin-based metabolites were not
360 quantified in the current study.

361 We found that a change (Day 90 – Day 0) in plasma concentrations of one anthocyanin
362 (malvidin-3-*O*-galactoside) at the postprandial timepoint was positively correlated with the change
363 (Day 90 – Day 0) in switch errors on the TST. In other words, individuals with greater
364 improvements on the TST had smaller increases in plasma concentrations of malvidin-3-*O*-
365 galactoside. In a previous study performed in rats supplemented with BB, malvidin-3-*O*-galactoside
366 was the most prevalent anthocyanin in the cortex, and correlational analysis found a positive
367 relationship between Morris water maze performance and the total number of anthocyanins found
368 in the cortex.³ It is possible that less malvidin-3-*O*-galactoside was found in the plasma as it had
369 been absorbed by the tissue. However, more work must be completed to further understand the
370 associations between anthocyanins and cognitive performance in humans and other model
371 organisms.

372 Phenolic acid derivatives were present in plasma at much higher concentrations than parent
373 anthocyanins. Research suggests that phenolic acid metabolites, derived from the metabolism of
374 anthocyanins, are the major compounds circulating in urine and blood after consumption of
375 anthocyanin-rich foods.²⁹⁻³⁰ Anthocyanins can be absorbed from the gastrointestinal lumen and
376 undergo presystemic metabolism in the intestinal wall or they can be metabolized to various
377 phenolic acids by bacteria in the colon.²⁹⁻³⁰ A significant increase in four phenolic acids (hippuric
378 acid, syringic acid, ferulic acid-glucuronide, and phloroglucinaldehyde) was observed in

379 postprandial samples after BB consumption for 90 days, compared to the control. Peak levels of
380 these compounds occurred on day 45 in the BB group, and an additional 45 days of
381 supplementation did not further increase the concentrations of these compounds in the plasma.

382 Ferulic acid-glucuronide was elevated at baseline (day 0) in both BB and control subjects
383 at the postprandial timepoint. This result was not surprising considering that the consumption of
384 breakfast cereals and other foods can significantly increase ferulic acid concentrations in the
385 blood.³¹ Contrary to other BB supplementation studies,^{15,20} post-hoc analysis did not show any
386 significant differences in ferulic acid-glucuronide levels between the BB and control groups at day
387 45 and 90. On the other hand, syringic acid and phloroglucinaldehyde were significantly elevated
388 in individuals from the BB group compared to the control at the postprandial timepoint only (day
389 45 and 90). When analyzing the associations between phenolic acid concentrations and measures
390 of cognition, we found that a change in ferulic acid-glucuronide in the BB group at the postprandial
391 timepoint was positively correlated with a change in switch errors on the TST but negatively
392 correlated with a change in repetition errors on the CVLT-II. Syringic acid was positively
393 correlated with a change in repetition errors only. These conflicting results could be partly due to
394 small sample size; however, it is clear that more studies are needed to further understand the
395 relationship between the bio- and neuro-availability of phenolic acids and the mechanisms by
396 which they directly or indirectly affect cognition and overall brain health in humans.

397 Lastly, hippuric acid was present in the highest concentration in plasma samples of the BB
398 group as has been shown in previous BB supplementation^{15,18,19,32} and strawberry supplementation
399 studies.²³ Furthermore, hippuric acid was the only phenolic acid that increased in concentration in
400 the BB group, compared to the control, at the fasting timepoint. This result is consistent with results
401 from previous berry intervention studies.^{33,34} Zhong and colleagues²⁰ characterized BB polyphenols

402 in plasma of subjects over a 24 h period after acute consumption of BB and found hippuric acid
403 increased significantly after 6 h and peaked 24 h post-consumption. Hippuric acid is a metabolite
404 of many polyphenols, including flavanols and anthocyanidins,^{33,35} and it is also generated from
405 protein and amino acid metabolism,³⁶ thus explaining the elevated levels at baseline (day 0) in the
406 BB and control group. In addition, hippuric acid was present in the highest concentration compared
407 to the other phenolic acids quantified. Feliciano and colleagues¹⁵ found hippuric acid to be the
408 biggest contributor to the polyphenol pool of metabolites in circulation (86%) following BB
409 supplementation for one month. Evidence for higher levels of hippuric acid in postprandial blood
410 samples of subjects supplemented with BB compared to the control could substantiate, in part,
411 improvements in cognitive function observed in BB supplementation studies. In this study, we
412 found that the change (Day 90 – Day 0) in hippuric acid levels in the BB group at the postprandial
413 timepoint was inversely correlated with the change in repetition errors on the CVLT-II, suggesting
414 that hippuric acid may have a beneficial effect on cognitive performance.

415 This study had both strengths and limitations. First, plasma samples were collected at only
416 two timepoints after chronic supplementation. Collecting blood samples at more timepoints
417 postprandially would have allowed a more complete pharmacokinetic analysis of BB polyphenol
418 metabolism. Second, urine analysis of polyphenol metabolites was not performed in this study and
419 would have allowed for total polyphenol absorption to be more accurately assessed. Third, a larger
420 sample size would make regression analyses more robust. Strengths included the use of a parallel
421 design making it possible to minimize issues with carryover; however, a cross-over design would
422 have made it easier to compare treatment effects within subjects. In addition, this study included
423 analysis of a wide array of phenolic acid and anthocyanin metabolites following blueberry
424 consumption over 90 days.

425 Future work is needed to further study the possible mechanisms underlying the cognitive
426 benefits observed in humans and animal models following chronic BB consumption. This work
427 should include blood analyses of growth factors such as insulin-like growth factor 1 (IGF-1) and
428 brain-derived neurotrophic factor (BDNF). Lower serum IGF-1 levels have been associated with
429 cognitive impairments in humans.^{37,38} Lower serum BDNF is associated with lower cognitive test
430 scores and mild cognitive impairment (MCI).³⁹ Overall, our results suggest that BB anthocyanins
431 are absorbed and extensively metabolized/catabolized resulting in the production of various
432 phenolic acid derivatives and their conjugates, all together contributing to the bioavailability and
433 beneficial effects associated with BB consumption. In conclusion, cognitive improvements are
434 related to changing levels of circulating phenolics.

435

436 **Conflicts of interest**

437 There are no conflicts of interest to declare

438 **Acknowledgements**

439 This research was funded by USDA intramural funds and agreements between the USDA and US
440 Highbush Blueberry Council. Freeze-dried blueberry and control powders were provided by the
441 US Highbush Blueberry Council. This clinical trial was conducted at the USDA Human Nutrition
442 Research Center on Aging at Tufts University. HPLC analysis of anthocyanins and phenolic acid
443 metabolites was conducted at the Illinois Institute of Technology. Marshall Miller's present
444 affiliation is the Center for the Study of Aging at Duke University Medical Center, Durham, NC.
445 Marshall Miller is currently supported by NIH T32 AG00002941.

446

447 **References**

- 448 1. E. L. Glisky, in *Brain Aging: Models, Methods, and Mechanisms*, ed. D. R. Riddle, CRC
449 Press/Taylor & Francis Group, Boca Raton, 2007.

- 450 2. M. G. Miller, N. Thangthaeng, S. M. Poulouse and B. Shukitt-Hale, Role of fruits, nuts, and
451 vegetables in maintaining cognitive health, *Exp. Gerontol.*, 2017, **94**, 24-28.
- 452 3. C. Andres-Lacueva, B. Shukitt-Hale, R. L. Galli, O. Jauregui, R. M. Lamuela-Raventos and J.
453 A. Joseph, Anthocyanins in aged blueberry-fed rats are found centrally and may enhance
454 memory, *Nutr. Neurosci.*, 2005, **8**, 111-120.
- 455 4. M. Giacalone, F. Di Sacco, I. Traupe, N. Pagnucci, F. Forfori and F. Giunta, in *Bioactive*
456 *Nutraceuticals and Dietary Supplements in Neurological and Brain Disease*, eds. R. R. Watson
457 and V. R. Preedy, Academic Press, San Diego, 2015.
- 458 5. B. Shukitt-Hale, D. F. Bielinski, F. C. Lau, L. M. Willis, A. N. Carey and J. A. Joseph, The
459 beneficial effects of berries on cognition, motor behaviour and neuronal function in ageing,
460 *Br. J. Nutr.*, 2015, **114**, 1542-1549.
- 461 6. A. N. Carey, S. M. Gomes and B. Shukitt-Hale, Blueberry supplementation improves memory
462 in middle-aged mice fed a high-fat diet, *J. Agric. Food Chem.*, 2014, **62**, 3972-3978.
- 463 7. S. Hein, A. R. Whyte, E. Wood, A. Rodriguez-Mateos and C. M. Williams, Systematic review
464 of the effects of blueberry on cognitive performance as we age, *J. Gerontol.*, 2019, **74**, 984-
465 995.
- 466 8. M. G. Miller, D. A. Hamilton, J. A. Joseph and B. Shukitt-Hale, Dietary blueberry improves
467 cognition among older adults in a randomized, double-blind, placebo-controlled trial, *Eur. J.*
468 *Nutr.*, 2018, **57**, 1169-1180.
- 469 9. A. R. Whyte and C. M. Williams, Effects of a single dose of a flavonoid-rich blueberry drink
470 on memory in 8 to 10 y old children, *Nutr. J.*, 2015, **31**, 531-534.

- 471 10. R. Krikorian, M. D. Shidler, T. A. Nash, W. Kalt, M. R. Vinqvist-Tymchuk, B. Shukitt-Hale
472 and J. A. Joseph, Blueberry supplementation improves memory in older adults, *J. Agric. Food*
473 *Chem.*, 2010, **58**, 3996-4000.
- 474 11. R. D. Rogers and S. Monsell, Costs of a predictable switch between simple cognitive tasks, *J.*
475 *Exp. Psychol. Gen.*, 1995, **124**, 207-231.
- 476 12. S. Monsell, N. Yeung and R. Azuma, Reconfiguration of task-set: Is it easier to switch to the
477 weaker task?, *Psychol. Res.*, 2000, **63**, 250-264.
- 478 13. S. Monsell, P. Sumner and H. Waters, Task-set reconfiguration with predictable and
479 unpredictable task switches, *Mem. Cogn.*, 2003, **31**, 327-342.
- 480 14. S. P. Woods, D. C. Delis, J. C. Scott, J. H. Kramer and J. A. Holdnack, The California Verbal
481 Learning Test – second edition: Test-retest reliability, practice effects, and reliable change
482 indices for the standard and alternate forms, *Arch. Clin. Neuropsych.*, 2006, **21**, 413-420.
- 483 15. R. P. Feliciano, G. Ista, C. Heiss and A. Rodriguez-Mateos, Plasma and urinary phenolic
484 profiles after acute and repetitive intake of wild blueberry, *Molecules*, 2016, **21**.
- 485 16. A. Rodriguez-Mateos, T. Cifuentes-Gomez, S. Tabatabaee, C. Lecras and J. P. E. Spencer,
486 procyanidin, anthocyanin, and chlorogenic acid contents of highbush and lowbush blueberries,
487 *J. Agric. Food Chem.*, 2012, **60**, 5772-5778.
- 488 17. J. Scalzo, A. Currie, J. Stephens, T. McGhie, P. Alspach and Horticulture and Food Research
489 Institute Of New Zealand Limited Hortresearch, The anthocyanin composition of different
490 *Vaccinium*, *Ribes* and *Rubus* genotypes, *Biofactors*, 2008, **34**, 13-21.
- 491 18. A. Rodriguez-Mateos, C. Rendeiro, T. Bergillos-Meca, S. Tabatabaee, T. W. George, C. Heiss
492 and J. P. Spencer, Intake and time dependence of blueberry flavonoid-induced improvements

- 493 in vascular function: a randomized, controlled, double-blind, crossover intervention study with
494 mechanistic insights into biological activity, *Am. J. Clin. Nutr.*, 2013, **98**, 1179-1191.
- 495 19. A. Rodriguez-Mateos, R. P. Feliciano, T. Cifuentes-Gomez and J. P. E. Spencer,
496 Bioavailability of wild blueberry (poly)phenols at different levels of intake, *J. Berry. Res.*,
497 2016, **6**, 137-148.
- 498 20. S. Zhong, A. Sandhu, I. Edirisinghe and B. Burton-Freeman, Characterization of wild
499 blueberry polyphenols bioavailability and kinetic profile in plasma over 24-h period in human
500 subjects, *Mol. Nutr. Food Res.*, 2017, **61**.
- 501 21. N. Travica, N. M. D'Cunha, N. Naumovski, K. Kent, D. D. Mellor, J. Firth, E. N.
502 Georgousopoulou, O. M. Dean, A. Loughman, F. Jacka and W. Marx, The effect of blueberry
503 interventions on cognitive performance and mood: A systematic review of randomized
504 controlled trials, *Brain Behav. Immun.*, 2020, **85**, 96-105.
- 505 22. J. L. Bowtell, Z. Aboo-Bakkar, M. E. Conway, A. R. Adlam and J. Fulford, Enhanced task-
506 related brain activation and resting perfusion in healthy older adults after chronic blueberry
507 supplementation, *Appl. Physiol. Nutr. Metab.*, 2017, **42**, 773-779.
- 508 23. A. K. Sandhu, M. G. Miller, N. Thangthaeng, T. M. Scott, B. Shukitt-Hale, I. Edirisinghe and
509 B. Burton-Freeman, Metabolic fate of strawberry polyphenols after chronic intake in healthy
510 older adults, *Food Funct.*, 2018, **9**, 96-106.
- 511 24. B. A. Sandoval-Ramírez, Ú. Catalán, S. Fernández-Castillejo, L. Rubió, A. Macià and R. Solà,
512 Anthocyanin tissue bioavailability in animals: Possible implications for human health. A
513 systematic review, *J. Agric. Food Chem.*, 2018, **66**, 11531-11543.

- 514 25. W. Kalt, J. B. Blumberg, J. E. McDonald, M. R. Vinqvist-Tymchuk, S. A. Fillmore, B. A.
515 Graf, J. M. O'Leary and P. E. Milbury, Identification of anthocyanins in the liver, eye, and
516 brain of blueberry-fed pigs, *J. Agric. Food Chem.*, 2008, **56**, 705-712.
- 517 26. A. K. Sandhu, Y. Huang, D. Xiao, E. Park, I. Edirisinghe and B. Burton-Freeman,
518 Pharmacokinetic characterization and bioavailability of strawberry anthocyanins relative to
519 meal intake, *J. Agric. Food Chem.*, 2016, **64**, 4891-4899.
- 520 27. W. Mullen, C. A. Edwards, M. Serafini and A. Crozier, Bioavailability of pelargonidin-3-O-
521 glucoside and its metabolites in humans following the ingestion of strawberries with and
522 without cream, *J. Agric. Food Chem.*, 2008, **56**, 713-719.
- 523 28. W. Kalt, Anthocyanins and their C(6)-C(3)-C(6) metabolites in humans and animals,
524 *Molecules*, 2019, **24**, 4024.
- 525 29. J. Fang, Some anthocyanins could be efficiently absorbed across the gastrointestinal mucosa:
526 Extensive presystemic metabolism reduces apparent bioavailability, *J. Agric. Food Chem.*,
527 2014, **62**, 3904-3911.
- 528 30. C. Czank, A. Cassidy, Q. Zhang, D. J. Morrison, T. Preston, P. A. Kroon, N. P. Botting and C.
529 D. Kay, Human metabolism and elimination of the anthocyanin, cyanidin-3-glucoside: a
530 (¹³C)-tracer study, *Am. J. Clin. Nutr.*, 2013, **97**, 995-1003.
- 531 31. A. Costabile, A. Klinder, F. Fava, A. Napolitano, V. Fogliano, C. Leonard, G. R. Gibson and
532 K. M. Tuohy, Whole-grain wheat breakfast cereal has a prebiotic effect on the human gut
533 microbiota: a double-blind, placebo-controlled, crossover study, *Br. J. Nutr.*, 2008, **99**, 110–
534 120.

- 535 32. A. Rodriguez-Mateos, R. Del Pino-García, T. W. George, A. Vidal-Diez, C. Heiss and J. P.
536 Spencer, Impact of processing on the bioavailability and vascular effects of blueberry
537 (poly)phenols, *Mol. Nutr. Food Res.*, 2014, **58**, 1952-1961.
- 538 33. C. Vetrani, A. A. Rivellese, G. Annuzzi, M. Adiels, J. Borén, I. Mattila, M. Orešič and A. M.
539 Aura, Metabolic transformations of dietary polyphenols: comparison between in vitro colonic
540 and hepatic models and in vivo urinary metabolites, *J. Nutr. Biochem.*, 2016, **33**, 111-118.
- 541 34. K. Hanhineva, M. A. Lankinen, A. Pedret, U. Schwab, M. Kolehmainen, J. Paananen, V. de
542 Mello, R. Sola, M. Lehtonen, K. Poutanen, M. Uusitupa and H. Mykkänen, Nontargeted
543 metabolite profiling discriminates diet-specific biomarkers for consumption of whole grains,
544 fatty fish, and bilberries in a randomized controlled trial, *J. Nutr.*, 2015, **145**, 7-17.
- 545 35. K. J. Penczynski, D. Krupp, A. Bring, K. Bolzenius, T. Remer and A. E. Buyken, Relative
546 validation of 24-h urinary hippuric acid excretion as a biomarker for dietary flavonoid intake
547 from fruit and vegetables in healthy adolescents, *Eur. J. Nutr.*, 2017, **56**, 757-766.
- 548 36. R. M. de Ferrars, C. Czank, Q. Zhang, N. P. Botting, P. A. Kroon, A. Cassidy and C. D. Kay,
549 The pharmacokinetics of anthocyanins and their metabolites in humans, *Br. J. Pharmacol.*,
550 2014, **171**, 3268-3282.
- 551 37. A. Angelini, C. Bendini, F. Neviani, L. Bergamini, B. Manni, T. Trenti, R. Rovati and M. Neri,
552 Insulin-like growth factor-1 (IGF-1): Relation with cognitive functioning and neuroimaging
553 marker of brain damage in a sample of hypertensive elderly subjects, *Arch. Gerontol. Geriatr.*,
554 2009, **49**, 5-12.
- 555 38. M. Picillo, R. Pivonello, G. Santangelo, C. Pivonello, R. Savastano, R. Auriemma, M. Amboni,
556 S. Scannapieco, A. Pierro, A. Colao, P. Barone and M. T. Pellecchia, Serum IGF-1 is

557 associated with cognitive functions in early, drug-naïve Parkinson's disease, *PLoS ONE*, 2017,
558 **12**, e0186508.

559 39. H. Shimada, H. Makizako, T. Doi, D. Yoshida, K. Tsutsumimoto, Y. Anan, K. Uemura, S.
560 Lee, H. Park and T. Suzuki, A large, cross-sectional observational study of serum BDNF,
561 cognitive function, and mild cognitive impairment in the elderly, *Front. Aging Neurosci.*, 2014,
562 **6**, 69-69.

563

564

565 **Table 2** Plasma phenolic acid concentrations (nmol L⁻¹) at fasting (t = 0 h) and 2 h after consuming the breakfast at days 0, 45, and 90.

	Treatment	Plasma concentrations (nmol L ⁻¹)					
		Fasting (0h)			Postprandial (2h)		
		Day 0	Day 45	Day 90	Day 0	Day 45	Day 90
<i>Phenolic Acids</i>							
3,4-dihydroxybenzoic acid	Control	37.4 ± 11.5	134.6 ± 110.3	23.9 ± 5.2	26.6 ± 5.3	24.9 ± 4.3	22.7 ± 4
	Blueberry	33.1 ± 8	31.1 ± 6.5	32.7 ± 4.3	27.1 ± 5.1	36.7 ± 6.3	36.6 ± 4.6
4-hydroxybenzaldehyde	Control	242.7 ± 29.1	256.9 ± 34.3	186.5 ± 19	242.3 ± 33.4	259 ± 27	220.6 ± 24.9
	Blueberry	216.2 ± 27.5	248.4 ± 33.8	171.1 ± 22.8	246.3 ± 34.6	265.4 ± 38	209.5 ± 37.8
4-Hydroxyphenylacetic acid	Control	619.3 ± 144	434.5 ± 121.6	435.2 ± 105	639.5 ± 107.1	551.6 ± 105.9	528.3 ± 128.3
	Blueberry	564.1 ± 108.6	574.3 ± 110.7	474.3 ± 88.3	678.9 ± 109.2	1205.9 ± 515.5	500.4 ± 76.7
Ferulic acid	Control	8 ± 5.1	1.1 ± 1.1	2.4 ± 1.7	26 ± 2.9	26.6 ± 4.3	26.7 ± 4
	Blueberry	1.6 ± 1.6	3.5 ± 2.6	2.4 ± 1.7	27.9 ± 4.7	36.2 ± 5	33.7 ± 5.4
Hippuric acid (μmol L ⁻¹) ^{† * ^ #}	Control	25.4 ± 7.2	12.6 ± 3	14.9 ± 3.7	18.8 ± 3.3	12.2 ± 2.5	16.3 ± 3.8
	Blueberry	20.2 ± 5.4	80.8 ± 8.4	71.1 ± 11.3	16.7 ± 4.3	63.8 ± 5.7	57.4 ± 8.5
Isovanillic acid [#]	Control	31.9 ± 22.5	6.2 ± 3	11.5 ± 4.1	114 ± 8.6	113.9 ± 11.7	106.9 ± 8.4
	Blueberry	13.6 ± 3.9	24.4 ± 4.6	20.2 ± 3.8	136.2 ± 11.9	151.7 ± 16.1	162.7 ± 17.5
p-coumaric acid	Control	3.2 ± 1.3	2.3 ± 0.7	1.9 ± 0.6	4.5 ± 0.8	7.6 ± 1.5	8 ± 1.3
	Blueberry	0.9 ± 0.4	1.8 ± 0.8	1.7 ± 0.5	3.5 ± 0.7	7.4 ± 1.6	8.3 ± 2.2
Phloroglucinaldehyde* [#]	Control	5.2 ± 1.7	3 ± 0.7	3.3 ± 0.5	3.6 ± 0.7	2.8 ± 0.6	3.3 ± 0.5
	Blueberry	3.4 ± 0.7	4.3 ± 0.8	4.1 ± 0.5	3.5 ± 1	12.7 ± 2	11.1 ± 1.4
Syringic acid* [#]	Control	15.7 ± 14	0.9 ± 0.9	1.1 ± 0.6	3.6 ± 1.9	3.5 ± 1.4	2.7 ± 0.9
	Blueberry	13.1 ± 7	3 ± 1.4	2.3 ± 0.9	3.9 ± 2.6	91.3 ± 18.1	71.3 ± 12.6
Trans-cinnamic acid [#]	Control	13.4 ± 5.2	3.7 ± 1.8	2.6 ± 1.4	24.9 ± 2.8	28.3 ± 3.4	24.5 ± 2.9
	Blueberry	14.5 ± 2.3	15.2 ± 3	193.4 ± 175.1	33.4 ± 2.6	36 ± 6	40.6 ± 5.1
Vanillic acid	Control	52 ± 52	0 ± 0	0 ± 0	324.3 ± 27.3	335.7 ± 35.6	347.6 ± 34.6
	Blueberry	0 ± 0	0 ± 0	0 ± 0	323.5 ± 34	444 ± 51.9	437 ± 53.6
Vanillic acid-glucuronide	Control	545.7 ± 346.6	183.5 ± 77.4	201 ± 49.6	2685.2 ± 279.4	2692.9 ± 326.7	2980.9 ± 334.8
	Blueberry	90.7 ± 31.9	416.5 ± 107.5	256.3 ± 70.1	2663.9 ± 258.2	3196.4 ± 369.4	3129.7 ± 361.8
Isovanillic acid-glucuronide	Control	126.9 ± 89.5	18.3 ± 10.2	27.9 ± 9.8	591.3 ± 64.8	515.8 ± 70.1	446.2 ± 44.3
	Blueberry	28.6 ± 10.8	54.9 ± 19.1	24 ± 11.1	683.2 ± 66.4	646.2 ± 59.9	603 ± 49.5
Ferulic acid-glucuronide*	Control	17.4 ± 8.8	3.9 ± 3.9	7.3 ± 5.1	58.4 ± 13.9	40 ± 13.1	38.9 ± 12.4
	Blueberry	4.3 ± 4.3	9.1 ± 6.3	6.7 ± 4.6	43.6 ± 10.4	70 ± 15.3	58.7 ± 13.8
3-CGA	Control	5 ± 2	2.3 ± 1.3	3.2 ± 2.5	34.8 ± 10.9	74.7 ± 45.5	42.8 ± 16.1
	Blueberry	7.4 ± 2.9	4.7 ± 3.8	4.4 ± 3.2	70 ± 19.5	64.5 ± 8.5	64.5 ± 13.5

Anthocyanins:

cyanidin-3- <i>O</i> -arabinoside [#]	Control	0 ± 0	0 ± 0	0 ± 0	0.5 ± 0.5	0 ± 0	0 ± 0
	Blueberry	0 ± 0	0.7 ± 0.7	0 ± 0	0.9 ± 0.9	3.5 ± 1.9	2.5 ± 0.7
Cyanidin-3- <i>O</i> -galactoside* [#]	Control	0 ± 0	0 ± 0	0 ± 0	0.8 ± 0.8	0 ± 0	0.7 ± 0.7
	Blueberry	0 ± 0	2.4 ± 1.6	0.5 ± 0.4	1.8 ± 1.8	18.5 ± 6.2	11.2 ± 2.3
Cyanidin-3- <i>O</i> -glucoside* [#]	Control	0 ± 0	0 ± 0	0 ± 0	0.4 ± 0.4	0 ± 0	0 ± 0
	Blueberry	0 ± 0	1 ± 1	0.3 ± 0.3	0 ± 0	4.2 ± 2.2	2.5 ± 0.9
Delphinidin-3- <i>O</i> -galactoside	Control	0 ± 0	0 ± 0	0 ± 0	1.3 ± 1.3	0 ± 0	0 ± 0
	Blueberry	0 ± 0	0 ± 0	0 ± 0	0 ± 0	3 ± 2	2.2 ± 0.9
Delphinidin-3- <i>O</i> -glucoside	Control	0 ± 0	0 ± 0	0 ± 0	0.7 ± 0.7	0 ± 0	0 ± 0
	Blueberry	0 ± 0	0 ± 0	0 ± 0	0 ± 0	1.5 ± 0.9	1.4 ± 0.8
Malvidin-3- <i>O</i> -arabinoside [#]	Control	0 ± 0	0 ± 0	0 ± 0	2 ± 2	0 ± 0	0 ± 0
	Blueberry	0 ± 0	1.4 ± 1.4	0 ± 0	1.9 ± 1.9	9.9 ± 7.6	7.8 ± 2.7
Malvidin-3- <i>O</i> -galactoside* [#]	Control	0 ± 0	0 ± 0	0 ± 0	2.7 ± 2.7	0 ± 0	0 ± 0
	Blueberry	0 ± 0	1.3 ± 1.3	0.5 ± 0.4	2.8 ± 2.8	29.5 ± 8.6	18 ± 4.5
Malvidin-3- <i>O</i> -glucoside* [#]	Control	0 ± 0	0 ± 0	0 ± 0	1.7 ± 1.7	0 ± 0	0 ± 0
	Blueberry	0 ± 0	2.3 ± 2.3	0 ± 0	2 ± 2	20.8 ± 8.3	12.4 ± 3.5
Peonidin-3- <i>O</i> -arabinoside	Control	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0
	Blueberry	0 ± 0	0.7 ± 0.7	0 ± 0	0 ± 0	1.5 ± 1.5	0 ± 0
Peonidin-3- <i>O</i> -galactoside [#]	Control	0 ± 0	0 ± 0	0 ± 0	0.4 ± 0.4	0 ± 0	0 ± 0
	Blueberry	0 ± 0	1.1 ± 1.1	0 ± 0	1.3 ± 1.3	3.6 ± 3.1	2.9 ± 2
Peonidin-3- <i>O</i> -glucoside [#]	Control	0 ± 0	0 ± 0	0 ± 0	0.5 ± 0.5	0 ± 0	0 ± 0
	Blueberry	0 ± 0	0 ± 0	0 ± 0	1.3 ± 1.3	3.7 ± 2.4	3.3 ± 1
Peonidin-3- <i>O</i> -xyloside* [#]	Control	0 ± 0	0 ± 0	0 ± 0	0.5 ± 0.5	0 ± 0	0 ± 0
	Blueberry	0 ± 0	0 ± 0	0 ± 0	0 ± 0	1.1 ± 0.5	1.9 ± 0.5
Peonidin glucuronide* [#]	Control	1.9 ± 1.9	0.7 ± 0.7	0 ± 0	15.4 ± 15.4	0 ± 0	0 ± 0
	Blueberry	0 ± 0	1.8 ± 1.8	0.2 ± 0.2	0 ± 0	150.7 ± 67.2	41 ± 18.1
Petunidin-3- <i>O</i> -galactoside [#]	Control	0 ± 0	0 ± 0	0 ± 0	1 ± 1	0 ± 0	0 ± 0
	Blueberry	0 ± 0	0.8 ± 0.8	0 ± 0	1.3 ± 1.3	3.4 ± 1.9	4.4 ± 1.2
Petunidin-3- <i>O</i> -glucoside* [#]	Control	0 ± 0	0 ± 0	0 ± 0	0.7 ± 0.7	0 ± 0	0 ± 0
	Blueberry	0 ± 0	0 ± 0	0 ± 0	0 ± 0	2.6 ± 1.2	1.4 ± 0.8

Values are presented as mean ± standard error of the mean. Significant intervention group (control and blueberry) by day (0, 45 and 90) interactions were observed at the [†]fasting and ^{*}postprandial timepoints ($p \leq 0.05$). Significant intervention group effects were observed at the [^]fasting and [#]postprandial timepoints ($p \leq 0.05$). Sample sizes: control N=19 and BB N=19. LOQ and LOD for these metabolites are found in Table S2.




Fig. 1 Study Schema. Blood samples were collected at fasting ($t = 0$ h) and 2 h after consuming breakfast on visits 2, 3, and 4. Breakfast included the control or blueberry drink on visits 3 and 4.

288x94mm (250 x 250 DPI)




Fig. 2 Circulating phenolic acid concentrations in plasma of subjects consuming blueberry (BB) or control at fasting (fast) and postprandial (post) timepoints. Two-way analysis of variance showed that BB significantly altered plasma concentrations of hippuric acid (A), syringic acid (B), ferulic acid-glucuronide (C), and phloroglucinaldehyde (D) at the postprandial time-point compared to control. Hippuric acid was the only phenolic compound that was significantly altered by BB at the fasting time-point. Data are represented as mean \pm SEM. Asterisk (*) denotes significant *post hoc* differences between treatments at fasting or postprandial timepoints ($p < 0.05$). Different letters denote significant *post hoc* differences within groups ($p < 0.05$).

279x215mm (200 x 200 DPI)




Fig. 3 Circulating anthocyanin concentrations in the plasma of subjects consuming blueberry (BB) or control at fasting (fast) and postprandial (post) timepoints. Two-way analysis of variance showed that BB significantly altered plasma concentrations of cyanidin-3-*O*-galactoside (A), cyanidin-3-*O*-glucoside (B), malvidin-3-*O*-galactoside (C), and malvidin-3-*O*-glucoside (D) at the postprandial time-point only. Data are represented as mean \pm SEM. Asterisk (*) denotes significant *post hoc* differences between treatments at fasting or postprandial timepoints ($p < 0.05$). Different letters denote significant *post hoc* differences within groups ($p < 0.05$).

279x215mm (200 x 200 DPI)




Fig. 4 Circulating anthocyanin concentrations in subjects consuming blueberry (BB) or control at fasting (fast) and postprandial (post) timepoints. Two-way analysis of variance showed that BB significantly altered plasma concentrations of petunidin-3-*O*-glucoside (A), peonidin glucuronide (B), and peonidin-3-*O*-xyloside (C) at the postprandial timepoint only. Data are represented as mean \pm SEM. Asterisk (*) denotes significant *post hoc* differences between treatments at fasting or postprandial timepoints ($p < 0.05$). Different letters denote significant *post hoc* differences within groups ($p < 0.05$).

255x181mm (200 x 200 DPI)




Fig. 5 Overall change (Day 90 – Day 0) in postprandial plasma phenolic levels vs. change (Day 90 – Day 0) in switch errors in the TST and repetition errors in the CVLT-II in subjects consuming BB. Change in (A) ferulic acid-glucuronide (A), syringic acid (B), and malvidin-3-*O*-galactoside (C) was significantly associated with a change in task switching errors ($R^2 = 0.521, p < 0.05$). Change in syringic acid (D), ferulic acid-glucuronide (E), and hippuric acid (F) was associated with a change in CVLT-II repetition errors ($R^2 = 0.807, p < 0.001$).

215x279mm (200 x 200 DPI)